Komrower Lecture: New names for old disciplines
Tóm tắt
Since the completion of the human genome map, genomics, proteomics and pharmacogenomics have become popular headings. In this review some 40 years of development in research and laboratory diagnosis of inborn errors of metabolism are summarized. It is shown that collaborative approaches of clinicians, geneticists, pathologists, biochemists and molecular biologists have contributed significantly to the (prenatal) diagnosis, genetic counselling and prevention of simple gene disorders, and in some instances to successful treatment. DNA technology widens the range to predictive risk testing for multifactorial disorders manifesting in adulthood. This offers new perspectives for potential patients and their close relatives, but also poses new psychosocial and ethical problems. Despite high expectations of new technologies in the development of new medicines for multifactorial disorders, examples of previous studies on the molecular etiology and pathogenesis of monogenic diseases indicate that a long way is ahead of us. Also the treatment of rare disorders and equal access to cure and care in the Third World need great attention.
Tài liệu tham khảo
Blackwood MA, Weber BL (1988) BRCA1 and BRCA2: from molecular genetics to clinical medicine. J. Clin Oncol 16: 1969–1977.
Buchdunger E, Matter A, Druker BJ (2001) BCR-Abl inhibition as a modality of CML therapeutics. Biochem Biophys 1551: 11–18.
Burke W, Pinsky LE, Press NA (2001) Categorizing genetic tests to identify their ethical, legal and social implications. Am J Med Genet 106(3): 233–240.
d'Azzo A, Hoogeveen A, Robinson D, et al (1982) Molecular defect in combined β-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci (USA) 79: 4535–4539.
d'Azzo A, Andria G, Strisciuglio P, Galjaard H (2001) Galactosialidosis. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3811–3826.
Deedwania P (2000) Global risk assessment in the presymptomatic patient. Am J Cardiol 11: 88 (7B): 17–22.
Druker BJ, Sawyers CL, Capdeville R, et al (2001) Chronic myelogenous leukemia. Hematology Jan. 87–112.
Dunlop MG, Farrington SM, Carothers AD, et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6: 105–110.
Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56: 265–271.
Evers-Kieboom G, Decruyenaere M, Frijns JP, et al (1997) Psychological consequences of presymptomatic testing for Huntington's disease. Lancet 349: 808.
Ford D, Easton DF, Shatton M, et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and 2 genes in breast cancer families. Am J Hum Genet 62: 676–689.
Freimer NB, Reus VI, Escamilla MA, et al (1996) Genetic mapping using haplotype, association and linkage methods rapports a locus for severe bipolar disorder (BPI) at 18 g 22–23. Nature Genetcs 12: 436–441.
Frets PG, Duivenvoorden HG, Verhage F, et al (1990) Factors influencing the reproductive decision after genetic counseling. Am J Med Genet 35: 496–502.
Friele MB (ed.) (2001) Embryo Experimentation in Europe; Biomedical, Legal and Philosophical Aspects. Bad Neuenahr, Ahrweiler: Europaïsche Akademie.
Frost MH, Schaid DJ, Sellers TA, et al (2000) Long-term satification and psychological and social function following bilateral prophylactic mastectomy. J Am Med Assoc 284: 310–324.
Galjaard H (1980) Genetic Metabolic Diseases; Early Diagnosis and Prenatal Analysis. Amsterdam: Elsevier.
Galjaard H (1994) Genetic technology in health care: A global view. Int J Technol Assess Health Care 10(4): 527–545.
Galjaard H, Hoogeveen A, Keijzer H, et al (1975) Genetic heterogeneity in GM1 gangliosidosis. Nature 257: 60–62.
Gershon D (1996) DNA diagnostic tools for the 21st century. Nature Medicine 1: 102–103.
Goldstein IL, Hobbs H, Brown MS (2001) Familial hypercholesterolemia. In Scriver CR, Beaudet AI, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2863–2914.
Goodfellow P (2002) Genomics, Genes and Drugs, Conference Genetics: Genie or Genius. HUGO-HGM. Public Form. Edinburgh. Personal communication.
Grabowski GA (1993) Gaucher disease enzymology, genetics and treatment. Adv Hum Genet 21: 377–441.
Hanash SM (2001) Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther 3(6): 538–545.
Harper P (2002) Practical Genetic Counseling, 6th edn. Oxford: Butterworth.
Hedera P (2001) Ethical principles and pitfalls of genetic testing for dementia. J Geriatr Psychiatry Neurol 14: 213–221.
Heutink P (2000) Untangling tau-related dementia. Hum Mol Genet 9: 979–986.
Holtzman NA (1997) Testing for genetic susceptibility to common cancers, clincal and ethical issues. Adv. Oncol 13: 9–15.
Human Genetics Commission (2001) Debating the Ethical Future of Human Genetics. First Annual Report of the HGC; PO Box 777, London.
Ida H, Rennert OM, Kobayashi M, et al (2001) Effects of enzyme replacement therapy in thirteen Japanese pediatric patients with Gaucher disease. Eur J Pediatr 160: 21–25.
Kleijer WJ (1999) Inborn errors of metabolism. In Rodeck CH, Whittle MJ, eds. Fetal Medicine: Basic Science and Clinical Practice. London: Churchill Livingstone, 525–541.
Lander ES, Linton LB, Birren B, et al (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921.
Langston AA, Malone KE, Thompson JD, et al (1996) BRCA 1 mutations in a population based sample of young women with breast cancer. N Engl J Med 334: 37–142.
Maguire CP, Kirby M, Coen R, Coakley D, Lawlor BA, O'Neil D (1996). Family members' attitudes towards telling the patient with Alzheimer's disease their diagnosis. Br Med J 313: 529–530.
Mark MF, Jenkins R, Miller WA (1997) Current applications of molecular cytogenetic technologies. Am Clin Lab. Sci. 27: 47–56.
Marshall A (1997) Getting the right drug into the right patient. Nature Biotechnology 15: 1249–1252.
Marteau T, Richards M (1996) The Troubled Helix; Social and Psychological Implications for the New Human Genetics. New York: Cambridge University Press.
McKusick VA (2002) Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/omim
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355: 2015–2020.
Macoska JA (2002) The progressive clinical utility of DNA micro arrays. CA Cancer J Clin 52(1): 50–59.
Oostra BA, Chiurazzi P (2001) The fragile X gene and its function. Clin Genet 60: 399–408.
Roses A (1994) The Alzheimer diseases. Curr Neurol 14: 111–141.
Roses (2002) How will healthcare delivery benefit from genetics? Conference: Genetics and Health—A Decade of Opportunity, January, London, UK.
Scriver CR, Beaudet AL, Sly WS, Valle D, et al (eds) (2001) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill.
Solter D, Gearhart I (1999) Putting stem cells to work. Science 283: 1468–1470.
Sykes R (1997) The New Genetics: a universal panacea or Pandora's Box? The Royal College of Physicians Lumleian Lecture. London: Glaxo Wellcome.
Tibben A, Timmerman R, Bannink EC, et al (1997) Three-years follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. Health Psychol 16: 20–35.
Todd JA, Farrall M (1996) Panning for gold: genome-wide scanning for linkages in type 1 diabetes Hum Mol Genet 5: 1443–1448.
Umans M, Deifesche JC, Sijbrands EJG, et al (2001) The results of the past 5 years of screening for familial hypercholesterolemia in The Netherlands. Lancet 357: 165–168.
UNDP (2002) United Nations Development Report. New York: United Nations Development Program.
UNESCO (2000a) The Universal Declaration on the Human Genome and Human Rights. Paris: UNESCO.
UNESCO (2000b) Solidarity and International Co-operation between developed and developing countries concerning the Human Genome. BIO-7/00/GT-2/2, Paris: UNESCO.
UNESCO (2001) The Use of Embryonic Stem Cells in Therapeutic Research. Report of The International Bioethics Committee. BIO-7/00/GT-1/2 Rev. 3. Paris: UNESCO.
van den Hout H, Reuser AJJ, Vulto AG, et al (2000) Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 356: 397–398.
van Duijn CM (1992) Risk factors for Alzheimer's disease. PhD Thesis, Erasmus University Rotterdam.
Vasen HFA, Nagengast FM, Kahn PM (1995) Interval cancers in hereditary non-polyposis colorectal cancer. Lancet 345: 1183–1184.
Veldman T, Vignon C, Schröck E, Rowley JD, et al (1997) Hidden chromosome abnormalities in hematological malignancies detected by multicolour spectral karyotyping. Nature Genetics 15: 404–410.
Venter CJ, Adams MD, Myers EW, et al (2001) The sequence of the human genome. Science 291: 1305–1351.
Verkerk AJ, Pieretti M, Sutcliffe JS, et al (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905–914.
Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9: 138–141.
Wenger DA, Tarby TJ, Wharton C (1978) Macular cherry red spots and myoclonus with dementia: co-existent neuraminidase and β-galactosidase deficiencies. Biochem Biophys Res Commun 82: 589–595.
Willemsen R, Oostra BA (2000) FMRP detection assay for the diagnosis of the fragile X-syndrome. Am J Med Genet 97: 183–188.
Willemsen R, Oosterwijk JC, Los FJ, et al (1996). Prenatal diagnosis of the fragile X-syndrome. Lancet 348: 967–968.
World Health Organization (1998) The World Health Report; Life in the 21st Century, A Vision for All. Geneva: WHO.